Mineralys Therapeutics, Inc. (MLYS) Misses Q3 EPS by 42c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St indexes climb after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 11, 2024 4:05 PM ESTCompleted enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025
Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025
Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025
Conference call today at 4:30 p.m. ET
RADNOR, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases... More
